InMed Pharmaceuticals Inc. Logo

InMed Pharmaceuticals Inc.

Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.

INM | US

Overview

Corporate Details

ISIN(s):
CA4576375022
LEI:
Country:
United States of America
Address:
1445-885 WEST GEORGIA ST., VANCOUVER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on developing a proprietary pipeline of small molecule drug candidates targeting the CB1 and CB2 receptors. The company's main therapeutic programs address significant unmet medical needs, including preclinical candidates for Alzheimer’s disease (INM-901) and dry age-related macular degeneration (INM-089), as well as a completed Phase 2 clinical trial for epidermolysis bullosa. Additionally, through its subsidiary BayMedica, InMed manufactures and supplies high-purity, bioidentical rare cannabinoids (including CBC, d9-THCV, CBDV, and CBTC) as raw ingredients for the B2B health and wellness product market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all InMed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for InMed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for InMed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea
308080
Viking Therapeutics, Inc. Logo
Biopharma developing novel therapies for metabolic and endocrine disorders like obesity and NASH.
United States of America
VKTX
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France
FR000
Vir Biotechnology, Inc. Logo
Immunology company developing antibody therapies for serious infectious diseases and cancer.
United States of America
VIR
Viridian Therapeutics, Inc.\DE Logo
Develops antibody therapies for rare autoimmune diseases, primarily Thyroid Eye Disease (TED).
United States of America
VRDN
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark
VIRO
Vistagen Therapeutics, Inc. Logo
Biopharma firm developing intranasal therapies for anxiety, depression & neurological disorders.
United States of America
VTGN
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway
VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany
V3V
Vivani Medical, Inc. Logo
Develops long-term subdermal drug implants for chronic diseases like diabetes & weight management.
United States of America
VANI

Talk to a Data Expert

Have a question? We'll get back to you promptly.